Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval

Core Viewpoint - Novo Nordisk's shares increased by 6% following the FDA's approval of its GLP-1 pill, marking a significant milestone as the world's first of its kind [1] Group 1: Product Approval and Market Position - The FDA's approval provides Novo Nordisk a competitive advantage over U.S. rival Eli Lilly in the GLP-1 market [1] - The GLP-1 pill will be available at a starting dose of 1.5 milligrams for $149 per month, accessible through pharmacies and select telehealth providers starting in early January [1] Group 2: Pricing Strategy and Consumer Access - Cash-paying patients can access the GLP-1 pill for the same price through TrumpRx, a direct-to-consumer website established by the Trump administration [2] - The pricing strategy aligns with the U.S. government's efforts to reduce consumer drug costs [2]